Aquatic Capital Management LLC Protagonist Therapeutics, Inc Transaction History

Aquatic Capital Management LLC

  • $3.8 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
SELL
$21.79 - $32.15 $139,456 - $205,760
-6,400 Reduced 73.56%
2,300 $66,000
Q4 2023

Feb 14, 2024
BUY
$14.05 - $23.44 $2,810 - $4,688
200 Added 2.35%
8,700 $199,000
Q3 2023

Nov 14, 2023
BUY
$16.68 - $23.66 $123,432 - $175,084
7,400 Added 672.73%
8,500 $142,000
Q2 2023

Aug 14, 2023
BUY
$18.02 - $29.36 $19,822 - $32,296
1,100 New
1,100 $30,000
Q4 2022

Feb 14, 2023
BUY
$7.36 - $11.17 $164,128 - $249,091
22,300 New
22,300 $243,000

Others Institutions Holding PTGX

# of Institutions
247
Shares Held
56.4M
Call Options Held
76.3K
Put Options Held
114K
View Full List

About Protagonist Therapeutics, Inc

PTGX Quotes by TradingView
  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Aquatic Capital Management LLC Portfolio

Follow Aquatic Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aquatic Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aquatic Capital Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email